The Journal of Urology
Volume 180, Issue 1 , Pages 367-372 , July 2008

Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386

  • Claudio Festuccia

      Affiliations

    • Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
    • Equal study contribution.
    • ,
  • Giovanni Luca Gravina

      Affiliations

    • Department of Surgery, University of L'Aquila, L'Aquila, Italy
    • Equal study contribution.
    • ,
  • Paola Muzi

      Affiliations

    • Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
    • ,
  • Roberto Pomante

      Affiliations

    • Pathology Department, G. Mazzini Hospital, Teramo, Italy
    • ,
  • Adriano Angelucci

      Affiliations

    • Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
    • ,
  • Carlo Vicentini

      Affiliations

    • Department of Surgery, University of L'Aquila, L'Aquila, Italy
    • ,
  • Mauro Bologna

      Affiliations

    • Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy
    • Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy
    • Corresponding Author InformationCorrespondence: Department of Experimental Medicine, Via Vetoio, Coppito-2, 67100 L'Aquila, Italy (telephone: 39 0862 433527; FAX: 39 0862 433523).

Received 24 September 2007

References 

  1. Russell DW, Wilson JD. Steroid 5α-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25
  2. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O'Brien SP, et al. Differential alterations in 5 alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231
  3. Thomas LN, Douglas RC, Vessey JP, Gupta R, Fontaine D, Norman RW, et al. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol. 2003;170:2019
  4. Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005;11:4365
  5. Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, et al. Prediction of prostate cancer for patients receiving finasteride: results from the prostate cancer prevention trial. J Clin Oncol. 2007;25:3076
  6. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006;12:4072
  7. Moss ML, Kuzmic P, Stuart JD, Tian G, Peranteau AG, Frye SV, et al. Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism. Biochemistry. 1996;35:3457
  8. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology. 1995;45:282
  9. Festuccia C, Angelucci A, Gravina GL, Muzi P, Vicentini C, Bologna M. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. J Cancer Res Clin Oncol. 2005;131:243
  10. Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58:130
  11. McCrohan MA, Morrissey C, O'Keane C, Mulligan N, Watson C, Smith J, et al. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer. 2006;106:2743
  12. Festuccia C, Angelucci A, Gravina GL, Muzi P, Miano R, Vicentini C, et al. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Int J Oncol. 2005;26:1353
  13. Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl. 2007;89:207
  14. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215
  15. Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja S, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007;28:763
  16. Gleave M, Qian J, Andreou C, Pommerville P, Chin J, Casey R, et al. The effects of the dual 5a-reductase inhibitor dutasteride on localized prostate cancer—results from a 4 month pre-radical prostatectomy study. Prostate. 2006;66:1674
  17. Heer R, Robson CN, Shenton BK, Leung HY. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J Cell Physiol. 2007;212:572
  18. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet. 2006;169:128
  19. Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, et al. Loss of PTEN is associated with progression to androgen independence. Prostate. 2006;66:895
  20. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, et al. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer. 2005;12:101

 Study received institutional review board approval.

 Supported by a grant from GlaxoSmithKline.

PII: S0022-5347(08)00529-6

doi: 10.1016/j.juro.2008.02.036

The Journal of Urology
Volume 180, Issue 1 , Pages 367-372 , July 2008

Article Tools

* Image Usage & Resolution